Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astrana HealthASTH +2.83%87 3-Year EBITDA Growth Rate is 3.70% as of Mar. 2026, which is 82% below its 10-year median of 20.20. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $83.12 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 529 Healthcare Providers & Services companies, Astrana Health ranks worse than 63.33% on this metric.
During the past 12 months, Astrana Health's average EBITDA Per Share Growth Rate was 23.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 22.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Astrana Health was 202.10% per year. The lowest was -414.30% per year. And the median was 20.20% per year.
Astrana Health (NAS:ASTH) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Astrana Health 3-Year EBITDA Growth Rate Related Terms
ASTH vs SGRY, SEM, MD: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Astrana Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astrana Health 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Astrana Health's 3-Year EBITDA Growth Rate falls into.
Astrana Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.70% mean?
Astrana Health (ASTH) has a 3-Year EBITDA Growth Rate of 3.70% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Astrana Health and its competitors. This is 82% below median its historical median of 20.20. According to the industry distribution chart, Astrana Health ranks #335 out of 529 companies in the Healthcare Providers & Services industry, placing it in the top 63.3%.
Is Astrana Health's 3-Year EBITDA Growth Rate too high?
Astrana Health's current 3-Year EBITDA Growth Rate of 3.70% is 82% below median its 10-year median of 20.20. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Astrana Health's value of 3.70% is 63.7% below this industry median. Based on the distribution chart, Astrana Health ranks #335 out of 529 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's 3-Year EBITDA Growth Rate compare to SGRY and SEM?
According to the Healthcare Providers & Services industry distribution chart, Astrana Health ranks #335 out of 529 companies for 3-Year EBITDA Growth Rate. This places Astrana Health in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Astrana Health's value of 3.70% is 63.7% below this benchmark. While the company's 10-year median is 20.20 vs. the industry median of 10.20, Astrana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astrana Health's current 3-Year EBITDA Growth Rate of 3.70% is 63.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Astrana Health and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astrana Health's current 3-Year EBITDA Growth Rate is 3.70%, which is 82% below median its own 10-year median of 20.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.12, compared to a current price of $49.00 — trading 41% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.70%, which is 82% below median its 10-year median of 20.20 and 63.7% below the Healthcare Providers & Services industry median of 10.20. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Astrana Health (ASTH), the current 3-Year EBITDA Growth Rate is 3.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astrana Health (ASTH) Overvalued in 2026?
Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued.
The current stock price of $49.00 is trading 41% below its estimated GF Value™ of $83.12.
GuruFocus considers Astrana Health to be Significantly Undervalued.
Key valuation signals for ASTH:
3-Year EBITDA Growth Rate: 3.70% (82% below median its 10-year median of 20.20)
GF Value™: $83.12 vs. price of $49.00 (41% below fair value)
Industry Position: 63.7% below the Healthcare Providers & Services median (#335 of 529)
No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score
Get the complete analysis for ASTH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASTH has been successfully added to your 
